Section Arrow
ZBIO.NASDAQ
- Zenas Biopharma Inc.
Quotes are at least 15-min delayed:2024/11/10 16:14 EST
Last
 21
+0.08 (+0.38%)
Day High 
21.821 
Prev. Close
20.92 
1-M High
26.2508 
Volume 
62.14K 
Bid
19.5
Ask
33.61
Day Low
20.64 
Open
21 
1-M Low
16.2 
Market Cap 
832.46M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 20.75 
20-SMA 21.14 
50-SMA -- 
52-W High 26.2508 
52-W Low 16.17 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.90/--
Enterprise Value
853.01M
Balance Sheet
Book Value Per Share
-7.26
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
50.00M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.0189+0.001+5.59%-- 
IOVAIovance Biotherapeutics10.585-1.695-13.80%-- 
SGMOSangamo Therapeutics2.87+0.06+2.14%-- 
ARDXArdelyx5.07-1.31-20.53%-- 
MRNAModerna46.84-3.44-6.84%-- 
Quotes are at least 15-min delayed:2024/11/10 16:14 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.